Allogenetics GmbH offers a completely new solution to the problem of organ rejection after transplantation. The Allogenetics approach is a unique first-in-class therapeutic as it treats the transplant instead of paralyzing the patient's immune system. This innovation offers a new dimension in organ transplantation: Invisible organs instead of lifelong immunosuppression.
The company's vision is to create immunological invisibility of donor organs by genetically modifying them to prevent rejection. Instead of inducing immunological blindness in the recipient, Allogenetics modifies donor organs to eliminate the expression of HLA antigens, which are the primary targets of immune rejection.
This approach enables a fully functional immune system in the recipient while preventing organ rejection, leading to better graft survival and improved quality of life. The technology involves ex vivo genetic modification during organ perfusion, using viral transduction to silence MHC genes and prevent protein expression on the cell surface.
Allogenetics' pipeline includes development programs for liver, heart, kidney, and lung transplants, with several in preclinical stages. The company aims to revolutionize transplantation by eliminating the need for lifelong immunosuppression.